SCHEMBL2313541

SCHEMBL2313541

CCCCNC(=O)NC(C)(C)C(=O)Nc1nc(-c2ccccc2)c(Cc2ccccc2)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.51
ALDH1A1 P00352 3/20 0.47
DGAT1 O75907 2/20 0.47
PLTP P55058 4/20 0.46
MAPT P10636 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HPGD P15428 2/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
ALOX5 P09917 1/20 0.41
XIAP P98170 1/20 0.41
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
ALOX12 P18054 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2316628 0.83 RORC (0.48) RORCALDH1A1DGAT1PLTPMAPT
SCHEMBL2312708 0.82 TP53 (0.50) RORCALDH1A1DGAT1PLTPMAPT
SCHEMBL2316445 0.81 RORC (0.51) RORCALDH1A1DGAT1PLTPMAPT
SCHEMBL2316643 0.81 PLTP (0.56) RORCALDH1A1DGAT1PLTPMAPT
SCHEMBL2318702 0.81 RORC (0.54) RORCALDH1A1DGAT1PLTPMAPT
SCHEMBL2316421 0.80 GAA (0.53) RORCALDH1A1DGAT1PLTPMAPT
SCHEMBL2320858 0.80 RORC (0.47) RORCALDH1A1DGAT1PLTPMAPT
SCHEMBL2316339 0.80 RORC (0.47) RORCALDH1A1DGAT1PLTPMAPT
SCHEMBL2316382 0.80 RORC (0.58) RORCALDH1A1DGAT1PLTPMAPT
SCHEMBL2485677 0.80 PLTP (0.51) RORCALDH1A1DGAT1PLTPMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
EP-2349484-A2 HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS Novartis AG (CH) 2011-08-03 EP disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 RORC 1166/4885ALDH1A1 139/4885DGAT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.